Our COVID-19 Research

Eyam’s self-amplifying mRNA vaccine platform designs low dose vaccines with advanced targeting for universal coverage and protection.

Our
COVID-19 Research

Eyam’s self-amplifying mRNA vaccine platform designs low dose vaccines with advanced targeting for universal coverage and protection.

mRNA vaccines are now in use with the COVID-19 global pandemic, but this is just the beginning…

We need to vaccinate over 7 billion people in a way that stops transmission, shuts down variants and, of paramount importance, does not create further variants. Current vaccines target only the Spike Protein and may not be effective in promoting long-term protection and immunity to SARS-CoV-2.

Eyam’s proprietary self-amplifying mRNA vaccine platform is designed to cover the original SARS-CoV-2 strain and the most threatening, emerging variants causing global concern.

mRNA vaccines are now in use with the COVID-19 global pandemic, but this is just the beginning…

We need to vaccinate over 7 billion people in a way that stops transmission, shuts down variants and, of paramount importance, does not create further variants. Current vaccines target only the Spike Protein and may not be effective in promoting long-term protection and immunity to SARS-CoV-2.

Eyam’s proprietary self-amplifying mRNA vaccine platform is designed to cover the original SARS-CoV-2 strain and the most threatening, emerging variants causing global concern.

VACCINES CANDIDATES

Targeting COVID-19 and variants of concern

In addition to the spike (S) protein, Eyam’s license with the University of British Columbia (UBC) allows for the inclusion of additional targets that may enhance vaccine immunogenicity. The license provides Eyam with the exclusive right to develop several proprietary COVID-19 vaccine candidates in a self-amplifying mRNA vaccine platform. Eyam is currently testing these COVID-19 vaccines candidates in preclinical trials.

VACCINES CANDIDATES

Targeting COVID-19 and variants of concern

In addition to the spike (S) protein, Eyam’s license with the University of British Columbia (UBC) allows for the inclusion of additional targets that may enhance vaccine immunogenicity. The license provides Eyam with the exclusive right to develop several proprietary COVID-19 vaccine candidates in a self-amplifying mRNA vaccine platform. Eyam is currently testing these COVID-19 vaccines candidates in preclinical trials.

The Problem

To date, mRNA Covid-19 vaccines target one specific protein, the spike glycoprotein (aka “spike protein”), which creates neutralizing antibodies against the novel coronavirus.

These spike-based mRNA vaccines have shown to lessen the severity of symptoms and decrease morbidity, but do not completely stop transmission.

Scientists anticipate that protection from these first generation vaccines will be short term with the need to create additional booster shots annually and ultimately next-generation vaccines to end the COVID-19 Pandemic.

Eyam’s Solution

Eyam activated its proprietary algorithm, the Jennerator, to target multiple proteins (not just the spike protein).

Anticipated Results

The creation of vaccines with long lasting universal protection and coverage, including against emerging variants.

Vaccine Candidates

Round 1:
5 second generation vaccines that specifically target the following variants:
Kent (UK) Variant, South African Variant, Brazilian Variant, California Variant and the original Wuhan Variant.

Round 2:
5 third generation vaccines with advanced targeting and proprietary vectors for higher efficacy and more advanced payload delivery.

Issues Addressed by Eyam’s COVID-19 Vaccines:

Viruses Mutate: Viruses are hyper variable as they can jump from animals to humans (zoonoses) and Covid-19 is no exception.

Spike Protein: First Gen Covid mRNA vaccines all only target the hyper variable spike protein.

Short Term Immunity: First Gen mRNA Covid vaccines are proving less effective against new variants.

“Leaky Vaccines”: Vaccines that cause partial immunity and fail to stop transmission allow for mutant viral escape and the possibility of new variants more resistant to vaccines.

Multi-Targeted Approach: Eyam’s Next Gen Vaccine Platform targets multiple proteins in the virus which aims to protect against future variants and create long-term immunity.

Issues Addressed by Eyam’s COVID-19 Vaccines:

Viruses Mutate: Viruses are hyper variable as they can jump from animals to humans (zoonoses) and Covid-19 is no exception.

Spike Protein: First Gen Covid mRNA vaccines all only target the hyper variable spike protein.

Short Term Immunity: First Gen mRNA Covid vaccines are proving less effective against new variants.

“Leaky Vaccines”: Vaccines that cause partial immunity and fail to stop transmission allow for mutant viral escape and the possibility of new variants more resistant to vaccines.

Multi-Targeted Approach: Eyam’s Next Gen Vaccine Platform targets multiple proteins in the virus which aims to protect against future variants and create long-term immunity.